Cargando…

High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine

As time has come to translate trial results into individualized medical diagnosis and therapy, we analyzed how to minimize residual risk of cardiovascular disease (CVD) by reviewing papers on “residual cardiovascular disease risk”. During this review process we found 989 papers that started off with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reijnders, E., van der Laarse, A., Jukema, J. W., Cobbaert, C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613690/ https://www.ncbi.nlm.nih.gov/pubmed/37908502 http://dx.doi.org/10.3389/fcvm.2023.1264319

Ejemplares similares

Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
por: Renee Ruhaak, L, et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Lipid‐lowering treatment patterns in patients with new cardiovascular events – estimates from population‐based register data in Sweden
por: Hallberg, S., et al.
Publicado: (2016)

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study
por: Jameson, K, et al.
Publicado: (2013)

Psycho-Cardiological Disease: A Bibliometric Review From 2001 to 2021
por: You, Yaping, et al.
Publicado: (2022)

Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life
por: Madeddu, Paolo, et al.
Publicado: (2019)

Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK
por: Danese, Mark, et al.
Publicado: (2022)

The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
por: Dhindsa, Devinder S., et al.
Publicado: (2020)

Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
por: Bodde, Mathijs C., et al.
Publicado: (2019)

Efficacy of Psycho-Cardiology therapy in patients with acute myocardial infarction complicated with mild anxiety and depression
por: Chen, Xiaoliang, et al.
Publicado: (2023)

Genetic association of lipids and lipid-lowering drugs with sepsis: a Mendelian randomization and mediation analysis
por: Lou, Chen, et al.
Publicado: (2023)

Editorial: Highlights in Lipids in Cardiovascular Disease: 2021
por: Boucheniata, Chaymae, et al.
Publicado: (2022)

Editorial: Insights in lipids in cardiovascular disease: 2021
por: Levitan, Irena, et al.
Publicado: (2022)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Editorial: Systems biology and data-driven machine learning-based models in personalized cardiovascular medicine
por: Hueso, Miguel, et al.
Publicado: (2023)

Targeting Lipid—Ion Channel Interactions in Cardiovascular Disease
por: Hudgins, Emma C., et al.
Publicado: (2022)

Personalized participatory medicine: sharing knowledge and uncertainty
por: Gurwitz, David, et al.
Publicado: (2011)

FRI085 Lipid Lowering Therapy Deficits In Secondary Cardiovascular Prevention In A Large Cohort From Eight Busy Clinics In Greece Over 12 Years
por: Paparodis, Rodis D, et al.
Publicado: (2023)

Machine Learning-Based Personalized Risk Prediction Model for Mortality of Patients Undergoing Mitral Valve Surgery: The PRIME Score
por: Zhou, Ning, et al.
Publicado: (2022)

Psycho-Social Medicine
Publicado: (1949)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Editorial: Crosstalk between lipid metabolism and ferroptosis in cardiovascular diseases
por: Liu, Yuliang, et al.
Publicado: (2023)

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options
por: Cesaro, Arturo, et al.
Publicado: (2023)

The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not At Goal study (SA-NAG)
por: Ramjeeth, Akash, et al.
Publicado: (2008)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community
por: Lieb, Wolfgang, et al.
Publicado: (2018)

Cohort profile: role of lipoproteins in cardiovascular disease—the LipidCardio study
por: König, Maximilian, et al.
Publicado: (2019)

Predictive, preventive, personalized and participatory medicine: back to the future
por: Auffray, Charles, et al.
Publicado: (2010)

Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention
por: Bodde, Mathijs C., et al.
Publicado: (2019)

Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation
por: Hessel, M. H. M., et al.
Publicado: (2007)

Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden
por: Karlsson, Sofia Axia, et al.
Publicado: (2019)

Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
por: Ying, Hangying, et al.
Publicado: (2021)

An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
por: Ruiz-Bustillo, Sonia, et al.
Publicado: (2022)

Corrigendum: Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
por: Ying, Hangying, et al.
Publicado: (2021)

Prime mover or fellow traveller: 25-hydroxy vitamin D’s seasonal variation, cardiovascular disease and death in the Scottish Heart Health Extended Cohort (SHHEC)
por: Tunstall-Pedoe, Hugh, et al.
Publicado: (2015)

Temporal Trends of System of Care for STEMI: Insights from the Jakarta Cardiovascular Care Unit Network System
por: Dharma, Surya, et al.
Publicado: (2014)

Psycho-cognitive behavioral problems in sleep disordered children☆
por: Karimzadeh, Parvaneh
Publicado: (2012)

Lipid-lowering therapy in older persons
por: Aronow, Wilbert S.
Publicado: (2015)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

The Associations of Lipid Profiles With Cardiovascular Diseases and Death in a 10-Year Prospective Cohort Study
por: Dong, Jiayi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mva062b1k81ja13qjecii3tbhp